SITC

Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights

Retrieved on: 
Monday, April 8, 2024
Research, SOC, Conference, CPI, Ono Pharmaceutical, Patient, Standard of care, Inflammation, Pembrolizumab, IND, Investigational New Drug, WT1, Nivolumab, SITC, FDA, Autoimmunity, Annual general meeting, Pharmaceutical industry

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.

Key Points: 
  • BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results.
  • The increase was due to revenue earned from our strategic collaboration agreement entered into with Ono Pharmaceutical in the first quarter of 2023.
  • As of December 31, 2023, the Company had approximately $48.5 million in cash, cash equivalents and marketable securities compared with $76.3 million as of December 31, 2022.
  • We expect our current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2025.

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

Retrieved on: 
Sunday, April 7, 2024
Skin cancer, Immunotherapy, Risk, Patient, SAN, RP1, University, MD Anderson Cancer Center, Society, AACR, Carcinoma, CSCC, SITC, PD-L1, Skin, Pharmaceutical industry

The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Key Points: 
  • The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
  • In the evaluable patient population (n=23), 20 had cutaneous squamous cell carcinoma (CSCC) and three had merkel cell carcinoma.
  • Of note, a patient treated with RP1 for CSCC also had a complete response of a new primary basal cell carcinoma which appeared post baseline.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers.

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Thursday, April 4, 2024
Toxicity, B cell, Conditional sentence, SOC, Survival, Survival rate, Chemoradiotherapy, Patient, Neoplasm, Tumor microenvironment, Standard of care, Doctor of Philosophy, Lymphocyte, Pancreatic cancer, Therapy, Cytokine, Injection, Pancreatitis, CD8, SITC, Recurrence, Valaciclovir, FDA, Annual general meeting, CADL, Food, Pharmaceutical industry

At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.

Key Points: 
  • At 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation.
  • Survival data were updated with eight months of further follow-up since the first analysis presented at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “We are very encouraged by the improved survival associated with CAN-2409, which has been shown to be durable after prolonged follow-up based on the updated data shown in this randomized clinical trial.
  • Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 2, 2024
Skin care, Research, Lung cancer, Ovarian cancer, DP, Head, Conference, Face, Cell, Skin cancer, Immunotherapy, TIL, Clinical, Cancer, Cervical cancer, HNSCC, George Washington University, Patient, Gene, American Academy, D&O, IND, Centricity, AACR, Glioblastoma, Skin, Breast cancer, Scalp, Melanoma, Patent, SITC, Private law, FDA, BRD4, Food, Pharmaceutical industry

MARLBOROUGH, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the year ended December 31, 2023 and provided a business update.

Key Points: 
  • The latter clearance was significant since there are no drugs specifically approved to treat early stages I and II of cSCC.
  • As of February, the first two patients in our first cohort have completed treatment with PH-762 with no reported adverse events.
  • In 2023 we implemented a cost rationalization program driven by our transition from discovery research to product development.
  • At December 31, 2023 we had cash of $8.5 million as compared with $11.8 million at December 31, 2022.

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
OS, Lung cancer, Research, Administration, Conference, Development, Prostate cancer, Survival, Immunotherapy, Fast track (FDA), HGG, Patient, Brain, Standard of care, MD, Society, Insurance, Pancreatic cancer, Clinical trial, Therapy, Breast cancer, SITC, FDA, CADL, Pharmaceutical industry

Research and Development Expenses: Research and development expenses were $7.3 million for the fourth quarter of 2023 compared to $5.0 million for the fourth quarter of 2022, and $24.5 million for the full year 2023 compared to $20.8 million for the full year 2022.

Key Points: 
  • Research and Development Expenses: Research and development expenses were $7.3 million for the fourth quarter of 2023 compared to $5.0 million for the fourth quarter of 2022, and $24.5 million for the full year 2023 compared to $20.8 million for the full year 2022.
  • General and Administrative Expenses: General and administrative expenses were $3.1 million for the fourth quarter of 2023 compared to $3.2 million for the fourth quarter of 2022, and $13.9 million for the full year 2023 compared to $14.1 million for the full year 2022.
  • The change from net other income in the fourth quarter of 2022 to net other expense in the fourth quarter of 2023 was primarily related to the change in the fair value of the Company’s warrant liability.
  • Cash Position: Cash and cash equivalents as of December 31, 2023 were $35.4 million, as compared to $70.1 million as of December 31, 2022.

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Retrieved on: 
Tuesday, March 26, 2024
Immunotherapy, Society, Therapy, ASCO, SITC, PRTG, Intensity, Annual general meeting, Pharmaceutical industry

WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS).

Key Points: 
  • WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS).
  • Portage was an early INTS investor and during the past few months, Portage has been able to monetize its equity holdings in INTS and bring in proceeds, net of related expenses, totaling $2.8M of non-dilutive funding.
  • The Company will use the proceeds to further fund its PORT-6 Phase 1a portion of the ADPORT-601 trial.
  • “We are excited with the potential of the Company’s adenosine platform and are focusing our efforts on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor) in selected solid tumors.”

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, March 26, 2024
Research, AXL, Head, Congress, NSCLC, SAN, Patient, Webcast, Observation, G&A, Peripheral neuropathy, CAB, Melanoma, D&O, Sarcoma, CD3, AACR, DLT, Conditional, ESMO, SITC, Therapy, ADC, Annual general meeting, SCCHN, Pharmaceutical industry

General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.

Key Points: 
  • General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.
  • Net loss for the quarter ended December 31, 2023 was $26.9 million compared to a net loss of $27.6 million for the same quarter in 2022.
  • Cash used for the quarter ended December 31, 2023 was $29.8 million.
  • Cash and cash equivalents as of December 31, 2023 were $111.5 million, compared to $215.5 million as of December 31, 2022.

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Monday, March 25, 2024
IIT, Radiation, IO, Carcinoma, Survival, NSCLC, Entrepreneurship, Monroe Dunaway Anderson, Patient, Journal, Merck, Overalls, MD, Lung, Neoplasm, Safety, EP, SITC, PFS, PD-L1, Platinum, Horn, Immunotherapy, PD-1, Medical imaging

This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.

Key Points: 
  • This Phase 2 trial will evaluate the efficacy and safety of Pembrolizumab, Plinabulin plus EP in 1L ES-SCLC.
  • KEYNOTE-604 study revealed that 12-month PFS rate in patients with pembrolizumab plus EP is 13.6% vs. 3.1% with placebo plus EP.
  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell Lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
  • An Open-Label, Single-Arm, Phase II Study of Pembrolizumab, Plinabulin Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer.

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Retrieved on: 
Thursday, March 21, 2024
Administration, Head, TIL, Colorectal cancer, Immunotherapy, HNSCC, Takeda Oncology, Selection, Patient, G&A, Melanoma, TILS, Investment, CRC, Breast cancer, SITC, Research and development, Research institute, Turnstone, Uveal melanoma

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Key Points: 
  • “2023 marked a transformative year for Turnstone Biologics in which we transitioned into a publicly traded company and continued to advance our pipeline through clinical development.
  • Recently, Turnstone expanded their trials to evaluate additional solid tumor types in addition to the existing indications of breast cancer and uveal melanoma.
  • Preclinical Data Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting Support Ongoing Clinical and Preclinical Efforts.
  • Cash, Cash Equivalents and Short-Term Investments: As of December 31, 2023, cash, cash equivalents and short-term investments were $94.8 million.

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Conference, Cancer, Immunotherapy, New Drug Application, Integral, CLDN6, Insurance, Society, Trial of the century, IND, CD3, SITC, Context, Annual general meeting, Food

PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights.

Key Points: 
  • “During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study.
  • The preclinical data further support CTIM-76’s differentiated product profile, including its potential to address limitations of first-generation CLDN6-targeted clinical-stage therapies,” said Martin Lehr, CEO of Context.
  • In November 2023, Context presented preclinical data at the SITC 38th Annual Meeting that demonstrated CTIM-76 was well tolerated and induced dose-proportional tumor regressions in xenograft models of CLDN6-positive cancer.
  • Context reported a net loss of $24.0 million for 2023, as compared to $14.8 million for the same period in 2022.